A new approach to staging diabetic eye disease: staging of diabetic retinal neurodegeneration and diabetic macular edema

Roomasa Channa; Risa M. Wolf; Rafael Simo; Mitchell Brigell; Patrice Fort; Christine Curcio; Stephanie Lynch; Frank Verbraak; Michael D. Abramoff; Diabetic Retinal Neurodegeneration and Macular Edema workgroup of the Moonshot initiative; Thomas W. Gardner

doi:10.1016/j.xops.2023.100420

Back

A new approach to staging diabetic eye disease: staging of diabetic retinal neurodegeneration and diabetic macular edema

Journal article

Open access

Peer reviewed

A new approach to staging diabetic eye disease: staging of diabetic retinal neurodegeneration and diabetic macular edema

Roomasa Channa, Risa M. Wolf, Rafael Simo, Mitchell Brigell, Patrice Fort, Christine Curcio, Stephanie Lynch, Frank Verbraak, Michael D. Abramoff, Diabetic Retinal Neurodegeneration and Macular Edema workgroup of the Moonshot initiative, …

Ophthalmology science (Online), Vol.4(3), 100420

05/2024

DOI: 10.1016/j.xops.2023.100420

PMCID: PMC10818256

PMID: 38284099

Files and links (1)

url

https://doi.org/10.1016/j.xops.2023.100420View

Published (Version of record) Open Access

Abstract

Topic The goal of this review was to summarize the current level of evidence on biomarkers to quantify diabetic retinal neurodegeneration (DRN) and diabetic macular edema (DME). Clinical relevance With advances in retinal diagnostics, we have more data on patients with diabetes than even before. However, the staging system for diabetic retinal disease is still based only on color fundus photographs and we do not have clear guidelines on how to incorporate data from the relatively newer modalities into clinical practice. Methods In this review, we use a Delphi process with experts to identify the most promising modalities to identify DRN and DME. These included microperimetry, full-field flash electroretinogram, spectral domain optical coherence tomography (OCT), adaptive optics and OCT-angiography. We then used a previously published method of determining evidence level to complete detailed evidence grids for each modality. Results Our results showed that among the modalities evaluated, the level of evidence to quantify DRN and DME was highest for OCT (level 1) and lowest for adaptive optics (level 4). Conclusion For most of the modalities evaluated, prospective studies are needed to elucidate their role in the management and outcomes of diabetic retinal diseases.

Details

Title: Subtitle: A new approach to staging diabetic eye disease: staging of diabetic retinal neurodegeneration and diabetic macular edema
Creators: Roomasa Channa - University of Wisconsin–Madison
Risa M. Wolf - Johns Hopkins Medicine
Rafael Simo - Vall d'Hebron Hospital Universitari
Mitchell Brigell
Patrice Fort - University of Michigan
Christine Curcio - University of Alabama at Birmingham
Stephanie Lynch
Frank Verbraak - Amsterdam University Medical Centers
Michael D. Abramoff - University of Iowa
Diabetic Retinal Neurodegeneration and Macular Edema workgroup of the Moonshot initiative
Thomas W. Gardner
Resource Type: Journal article
Publication Details: Ophthalmology science (Online), Vol.4(3), 100420
DOI: 10.1016/j.xops.2023.100420
PMID: 38284099
PMCID: PMC10818256
NLM abbreviation: Ophthalmol Sci
ISSN: 2666-9145
eISSN: 2666-9145
Language: English
Electronic publication date: 10/2023
Date published: 05/2024
Academic Unit: Electrical and Computer Engineering; Fraternal Order of Eagles Diabetes Research Center; Ophthalmology and Visual Sciences
Record Identifier: 9984505060102771

Metrics

65 Record Views

See more details